Ablation using high-intensity focused ultrasound can effectively control some types of localized prostate cancer for five years or longer, according to a study by German researchers.
Ablation using high-intensity focused ultrasound can effectively control some types of localized prostate cancer for five years or longer, according to a study by German researchers.
Dr. Andreas Blana and colleagues at the University of Regensburg's St. Josef Hospital evaluated results from 140 patients with early or intermediate localized prostate cancer who underwent treatment across
Europe between 1997 and 2001. Follow-up prostate biopsies were negative in 86.4% of patients who underwent focused ultrasound ablation, with a five-year PSA-related failure-free survival rate of 77%. The overall disease-free rate at five and seven years was 66% and 59%, respectively. Findings were published online Nov. 5 in European Urology.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.